Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres

Drug and Alcohol Dependence

Volumn 94, Issue 1-3, 2008, Pages 125-132

  Leonardi, C ^a   Hanna, N ^a   Laurenzi, P ^a   Fagetti, R ^a  

^a ASL Roma B   (Italy)

Author keywords

Addiction; Buprenorphine; Opioid; Treatment

Indexed keywords

BUPRENORPHINE; COCAINE; METHADONE;

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; ITALY; MAINTENANCE THERAPY; OBSERVATIONAL STUDY; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RELAPSE;

ADULT; BUPRENORPHINE; COCAINE; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NARCOTICS; OBSERVATION; OPIOID-RELATED DISORDERS; PSYCHOLOGY; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE TREATMENT CENTERS;

EID: 39149088931     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.10.017     Document Type: Article

References (38)

1. Amass L., Bickel W.K., Crean J.P., Blake J., and Higgins S.T. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berl.) 136 (1998) 217-225
2. Amass L., Kamien J.B., and Mikulich S.K. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend. 61 (2001) 173-181
3. Auriacombe M., Franques P., and Tignol J. Deaths attributable to methadone versus buprenorphine in France. JAMA 285 (2001) 45
4. Auriacombe M., Fatseas M., Dubernet J., Daulouede J.P., and Tignol J. French field experience with buprenorphine. Am. J. Addict. 13 (2004) S17-S28
5. Breen C.L., Harris S.J., Lintzeris N., Mattick R.P., Hawken L., Bell J., Ritter A.J., Lenne M., and Mendoza E. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend. 71 (2003) 49-55
6. Butcher J.N., Williams C.L., Graham J.R., Archer R.P., Tellegen A., Ben-Porath Y.S., and Kaemmer B. MMPI-A: Manual for Administration, Scoring and Interpretation (1992), University of Minnesota Press
7. Chang Y., and Moody D.E. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur. J. Clin. Pharmacol. 60 (2005) 875-881
8. Ciraulo D.A., Hitzemann R.J., Somoza E., Knapp C.M., Rotrosen J., Sarid-Segal O., Ciraulo A.M., Greenblatt D.J., and Chiang C.N. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J. Clin. Pharmacol. 46 (2006) 179-192
9. Deodato S., Scaglia M., Spiller V., and Guelfi G.P. Uno strumento per la valutazione della motivazione al cambiamento nelle tossicodipendenze: il Readiness To Change Questionnaire (R.T.C.Q.). Bollettino delle Farmacodipendenze e Alcolismo, vol. XVIII (1995) 3
10. Di Petta G., and Leonardi C. Buprenorphine high-dose, broad spectrum, long-term treatment: a new clinical approach to opiate alkaloid dependency. Heroin. Add. Rel. Clin. Probl. 7 (2005) 21-26
11. Eder H., Fischer G., Gombas W., Jagsch R., Stuhlinger G., and Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur. Addict. Res. 4 (1998) 3-7
12. Gibson A.E., Doran C.M., Bell J.R., Ryan A., and Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med. J. Aust. 179 (2003) 38-42
13. Iribarne C., Picart D., Dreano Y., and Berthou F. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam. Clin. Pharmacol. 12 (1998) 194-199
14. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., and Bigelow G.E. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 40 (1995) 27-35
15. Johnson R.E., Strain E.C., and Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 21 (2003) S59-S77
16. Kilicarslan T., and Sellers E.M. Lack of interaction of buprenorphine with flunitrazepam metabolism. Am. J. Psychiatry 157 (2000) 1164-1166
17. Kosten T.R., Schottenfeld R., Ziedonis D., and Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181 (1993) 358-364
18. Krantz M.J., and Mehler P.S. Treating opioid dependence. Growing implications for primary care. Arch. Intern. Med. 164 (2004) 277-288
19. Kristensen O., Espegren O., Asland R., Jakobsen E., Lie O., and Seiler S. Buprenorphine and methadone to opiate addicts-a randomized trial. Tidsskr Nor Laeforen 125 (2005) 148-151
20. Ling W., Charuvastra C., Collins J.F., Batki S., Brown Jr. L.S., Kintaudi P., Wesson D.R., McNicholas L., Tusel D.J., Malkerneker U., Renner Jr. J.A., Santos E., Casadonte P., Fye C., Stine S., Wang R.I., and Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93 (1998) 475-486
21. Lintzeris N., Rushworth L., Bammer G., Main N., Bell J., Weeks C., Jolley D., Mazengarb J., MacQueen R., and Whelan G. Res. Clin. Forums 23 (2001) 49-60
22. Lucchini, A., Leonardi, C., 2003. L'uso della buprenorfina nel trattamento della tossicodipendenza. Due Anni di Esperienze nei Ser.T. Franco Angeli Editore.
23. Marsch L.A., Bickel W.K., Badger G.J., and Jacobs E.A. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend. 77 (2005) 195-204
24. Mattick, R.P., Kimber, J., Breen, C., Davoli, M., 2004. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. CD002207.
25. McCance-Katz E.F. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin. Infect. Dis. 41 (2005) S89-S95
26. McCance-Katz E.F., Rainey P.M., Friedland G., Kosten T.R., and Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am. J. Addict. 10 (2001) 296-307
27. Miller W.R., and Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior (1991), Guilford, New York
28. Oliveto A.H., Feingold A., Schottenfeld R., Jatlow P., and Kosten T.R. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine versus methadone. Arch. Gen. Psychiatry 56 (1999) 812-820
29. Petitjean S., Stohler R., Deglon J.J., Livoti S., Waldvogel D., Uehlinger C., and Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 62 (2001) 97-104
30. Petry N.M., Bickel W.K., and Badger G.J. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addiction 96 (2001) 823-834
31. Prochaska J.O., and DiClemente C.C. Transtheoretical therapy: toward a more integrative model of change. Psychother.: Theory Res. Pract. 19 (1982) 276-288
32. Reynaud M., Petit G., Potard D., and Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93 (1998) 1385-1392
33. Schottenfeld R.S., Pakes J., Ziedonis D., and Kosten T.R. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry 34 (1993) 66-74
34. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., and Kosten T.R. Buprenorphine versus methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch. Gen. Psychiatry 54 (1997) 713-720
35. Schottenfeld R.S., Chawarski M.C., Pakes J.R., Pantalon M.V., Carroll K.M., and Kosten T.R. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am. J. Psychiatry 162 (2005) 340-349
36. Spiller, V., Guelfi, G.P., 1998. La valutazione della motivazione al cambiamento. Il Questionario MAC/E. Bollettino Farmacodipendenze e Alcolismo No. 2.
37. Vigezzi P., Guglielmino L., Marzorati P., Silenzio R., De Chiara M., Corrado F., Cocchi L., and Cozzolino E. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin and cocaine-dependant patients. J. Subst. Abuse Treat. 31 (2006) 3-7
38. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., and Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55 (1994) 569-580